Overview
Public BiotechPhase 3psilocybinDMT
Formerly Cybin Inc., rebranded to Helus Pharma in January 2026. Developing CYB003 (deuterated psilocybin) for major depressive disorder in Phase 3 trials, and CYB004 for generalized anxiety disorder.
Visit WebsiteToronto, Canada
$300M
Market Cap
2019
Founded
70
Employees
0
Open Roles
Open Positions
No open positions at this time
Research Areas
Clinical Pipeline(6)
Recruiting·Phase 3·psilocybin
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
CYB003Major Depressive Disorder (MDD)
Withdrawn·Phase 2·psilocybin
Effect of SSRIs on Response to Psilocybin Therapy
PsilocybinDepression
Enrolling by Invitation·Phase 3·psilocybin
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
CYB003Major Depressive Disorder
Recruiting·Phase 3·psilocybin
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
CYB003Major Depressive Disorder
Active, Not Recruiting·Phase 2·DMT
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
CYB004Generalized Anxiety Disorder
Completed·Phase 1·psilocybin
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
CYB003Major Depressive Disorder